O'Shaughnessy Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

O'Shaughnessy Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,363	Closed	-$287K	–	2395
2024 Q4	$287K	Sell	2,363 -1,476	-38%	-$181K	﹤0.01%	1554
2024 Q3	$477K	Buy	3,839 +1,590	+71%	+$220K	﹤0.01%	1251
2024 Q2	$355K	Buy	+2,249	New	+$289K	﹤0.01%	1276
2021 Q4	–	Sell	-441	Closed	-$41K	–	2324
2021 Q3	$41K	Sell	441 -248	-36%	-$19.1K	﹤0.01%	1729
2021 Q2	$54K	Buy	689 +11	+2%	+$834	﹤0.01%	1557
2021 Q1	$50K	Sell	678 -946	-58%	-$87.3K	﹤0.01%	1402
2020 Q4	$277K	Buy	1,624 +1,546	+1,982%	+$229K	0.01%	715
2020 Q3	$11K	Buy	78 +46	+144%	+$6.99K	﹤0.01%	1343
2020 Q2	$5K	Buy	+32	New	+$4.36K	﹤0.01%	1383
2020 Q1	–	Sell	-1	Closed	–	–	1765
2019 Q4	$0	Buy	+1	New	+$101	﹤0.01%	1897

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

O'Shaughnessy Asset Management's SRPT Position: Q1 2025 in Review

O'Shaughnessy Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,363 shares — an estimated $287K sold.

O'Shaughnessy Asset Management first reported a position in SRPT in Q4 2019 and held it in 10 quarters. The position peaked at $477K in Q3 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

O'Shaughnessy Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
O'Shaughnessy Asset Management sold 2,363 Sarepta Therapeutics shares in Q1 2025, an estimated $287K.
O'Shaughnessy Asset Management first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 10 quarters.
O'Shaughnessy Asset Management's Sarepta Therapeutics position peaked at $477K in Q3 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2025, filed 13 May 2025.